(Reuters) – Hikma Pharma on Thursday forecast core operating margin growth for its generics business at the upper end of its earlier guidance for this year, helped by strong revenue from its sodium oxybate generic drug.
The drugmaker’s generics business is now expected to post core operating margin growth of around 20%, the top-end of its previous outlook range of 18%-20%, for the year ending Dec.
31.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Mrigank Dhaniwala)
